Although AURKB has long been recognized as a pan-cancer therapeutic target, the clinical efficacy of AURKB inhibitors has remained disappointing [13–17], raising concerns regarding non-classical, kinase-independent carcinogenic mechanisms. The gene discussed is AURKB; the disease is cancer.